Efficacy of subconjunctival bevacizumab injections before and after surgical excision in preventing pterygium recurrence
Completed
- Conditions
- PterygiumEye Diseases
- Registration Number
- ISRCTN11424742
- Lead Sponsor
- S. Luigi Gonzaga University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 80
Inclusion Criteria
1. Aged over 18 years
2. Pterygium in one/both eye(s) extending more than 1 mm across the limbus
Exclusion Criteria
1. Pregnancy
2. Ocular surface disease or infection
3. Autoimmune disorders
4. Previous limbal or corneal surgery
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Recurrence of pterygium (defined by growth of fibrovascular tissue extending more than 1 mm across the limbus), assessed by ophthalmological examination during follow-up visits at 1 week, 1 month, 3 and 6 months after the second subconjunctival injection (for the study group) or after surgery (for the control group).
- Secondary Outcome Measures
Name Time Method 1. Grading of pterygium vascularization (according to the scheme proposed by Tan et al., Arch Ophthalmol 1997), assessed by ophthalmological examination during follow-up visits at 1 day, 1 month, 3 and 6 months after the second subconjunctival injection (for the study group) or after surgery (for the control group)<br>2. Pterygium dimensions, assessed by comparison of ocular anterior segment photographs captured 1 week before treatment with pictures captured at 1 week, 1 month 3 and 6 months follow-up visits